Healthcare Swedish Community

1. The Narrative: The High Tech Precision Play The narrative for RaySearch is that of a highly specialized software leader in the oncology market.Read more

EQL Pharma is pushing hard to expand its range of everyday medicines, with a growing lineup of new products that could keep sales climbing fast. The catch is that the shares already reflect a lot of optimism, and execution plus cash flow need to keep up for the story to work.Read more

A small Swedish biotech is trying to make medicines work better and last longer in the body by wrapping them in a protective “shell.” The big question is whether this delivery tech can attract major partners and turn early promise into real products—before setbacks or slow adoption get in the way.Read more

Dedicare supplies health and social care staff in a region where ageing populations and ongoing staff shortages keep demand strong. The catch is that tougher rules and fiercer rivals are squeezing results, and the story hinges on whether Dedicare can defend its position while expanding into new markets.Read more

OssDsign is reshaping itself around bone-regeneration materials, and early signs suggest this focus could help it win more hospitals—especially in the U.S.—thanks to growing clinical evidence and product features surgeons value. The big question is whether it can keep that momentum while navigating tough competition, lumpy customer demand, and the approvals it needs to expand.Read more

Vimian rides long-term demand for animal health, but its deal-heavy growth and debt could start to bite as borrowing gets pricier and trade rules shift. See why tariffs, softer demand in parts of the U.S. business, and rising pressure from bigger clinic groups may make the company’s growth look less predictable than many expect.Read more

Sectra’s big bet on moving medical imaging into the cloud could come with an underappreciated downside: rising data and computing costs and slower rollouts at hospitals may squeeze profits even if demand keeps growing. See why this view argues the company’s long-term upside may be capped unless it can keep costs under control while expanding into new diagnostic tools.Read more

Immunovia is moving its pancreatic cancer blood test from development into a careful national rollout, betting that more doctors will add simple blood screening alongside scans for people at high risk. The upside hinges on insurance coverage and smoother lab processing catching up over time—while delays could force more fundraising and slow growth.Read more

Mentice sells virtual training tools that help doctors and medical device companies plan and practice image-guided procedures, and growing demand for these procedures could make its business steadier over time. A shift toward more subscription-style software and a more portable system may lift repeat sales, but tight hospital budgets and uneven ordering could slow the turnaround.Read more